Why the study?
Does the combination of UT-15C and PDE5 inhibitors augment ATP release from erythrocytes of humans with pulmonary arterial hypertension?
Does the combination of UT-15C and PDE5 inhibitors augment ATP release from erythrocytes of humans with pulmonary arterial hypertension?
Prostacyclin analogs and PDE5 inhibitors work synergistically to enhance the release of the vasodilator ATP from PAH erythrocytes, providing a mechanistic rationale for their co-administration.
No takes yet. Share an insight, caveat, or question.
May support combined prostacyclin-PDE5 inhibitor use in PAH via erythrocyte ATP release; leaves open clinical translation from Level 5 data.
Bowles et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: